Cardiac fibrosis in the ageing heart

Contributors and mechanisms

Lu Lu, Jingbin Guo, Yue Hua, Kevin Huang, Ruth Magaye, Jake Cornell, Darren J. Kelly, Christopher Reid, Danny Liew, Yingchun Zhou, Aihua Chen, Wei Xiao, Qiang Fu, Bing Hui Wang

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)

Abstract

Cardiac fibrosis refers to an excessive deposition of extracellular matrix (ECM) in cardiac tissue. Fibrotic tissue is stiffer and less compliant, resulting in subsequent cardiac dysfunction and heart failure. Cardiac fibrosis in the ageing heart may involve activation of fibrogenic signalling and inhibition of anti-fibrotic signalling, leading to an imbalance of ECM turnover. Excessive accumulation of ECM such as collagen in older patients contributes to progressive ventricular dysfunction. Overexpression of collagen is derived from various sources, including higher levels of fibrogenic growth factors, proliferation of fibroblasts and cellular transdifferentiation. These may be triggered by factors, such as oxidative stress, inflammation, hypertension, cellular senescence and cell death, contributing to age-related fibrotic cardiac remodelling. In this review, we will discuss the fibrogenic contributors in age-related cardiac fibrosis, and the potential mechanisms by which fibrogenic processes can be interrupted for therapeutic intent.

Original languageEnglish
Pages (from-to)55-63
Number of pages9
JournalClinical and Experimental Pharmacology and Physiology
Volume44
Issue numberS1
DOIs
Publication statusPublished - 1 Dec 2017

Keywords

  • ageing
  • cardiac fibrosis
  • extracellular matrix turnover
  • fibrogenic factors
  • heart failure

Cite this

Lu, Lu ; Guo, Jingbin ; Hua, Yue ; Huang, Kevin ; Magaye, Ruth ; Cornell, Jake ; Kelly, Darren J. ; Reid, Christopher ; Liew, Danny ; Zhou, Yingchun ; Chen, Aihua ; Xiao, Wei ; Fu, Qiang ; Wang, Bing Hui. / Cardiac fibrosis in the ageing heart : Contributors and mechanisms. In: Clinical and Experimental Pharmacology and Physiology. 2017 ; Vol. 44, No. S1. pp. 55-63.
@article{90ccae1aceda41b98db71edbd7bfa979,
title = "Cardiac fibrosis in the ageing heart: Contributors and mechanisms",
abstract = "Cardiac fibrosis refers to an excessive deposition of extracellular matrix (ECM) in cardiac tissue. Fibrotic tissue is stiffer and less compliant, resulting in subsequent cardiac dysfunction and heart failure. Cardiac fibrosis in the ageing heart may involve activation of fibrogenic signalling and inhibition of anti-fibrotic signalling, leading to an imbalance of ECM turnover. Excessive accumulation of ECM such as collagen in older patients contributes to progressive ventricular dysfunction. Overexpression of collagen is derived from various sources, including higher levels of fibrogenic growth factors, proliferation of fibroblasts and cellular transdifferentiation. These may be triggered by factors, such as oxidative stress, inflammation, hypertension, cellular senescence and cell death, contributing to age-related fibrotic cardiac remodelling. In this review, we will discuss the fibrogenic contributors in age-related cardiac fibrosis, and the potential mechanisms by which fibrogenic processes can be interrupted for therapeutic intent.",
keywords = "ageing, cardiac fibrosis, extracellular matrix turnover, fibrogenic factors, heart failure",
author = "Lu Lu and Jingbin Guo and Yue Hua and Kevin Huang and Ruth Magaye and Jake Cornell and Kelly, {Darren J.} and Christopher Reid and Danny Liew and Yingchun Zhou and Aihua Chen and Wei Xiao and Qiang Fu and Wang, {Bing Hui}",
year = "2017",
month = "12",
day = "1",
doi = "10.1111/1440-1681.12753",
language = "English",
volume = "44",
pages = "55--63",
journal = "Clinical and Experimental Pharmacology and Physiology",
issn = "0305-1870",
publisher = "Wiley-Blackwell",
number = "S1",

}

Lu, L, Guo, J, Hua, Y, Huang, K, Magaye, R, Cornell, J, Kelly, DJ, Reid, C, Liew, D, Zhou, Y, Chen, A, Xiao, W, Fu, Q & Wang, BH 2017, 'Cardiac fibrosis in the ageing heart: Contributors and mechanisms', Clinical and Experimental Pharmacology and Physiology, vol. 44, no. S1, pp. 55-63. https://doi.org/10.1111/1440-1681.12753

Cardiac fibrosis in the ageing heart : Contributors and mechanisms. / Lu, Lu; Guo, Jingbin; Hua, Yue; Huang, Kevin; Magaye, Ruth; Cornell, Jake; Kelly, Darren J.; Reid, Christopher; Liew, Danny; Zhou, Yingchun; Chen, Aihua; Xiao, Wei; Fu, Qiang; Wang, Bing Hui.

In: Clinical and Experimental Pharmacology and Physiology, Vol. 44, No. S1, 01.12.2017, p. 55-63.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Cardiac fibrosis in the ageing heart

T2 - Contributors and mechanisms

AU - Lu, Lu

AU - Guo, Jingbin

AU - Hua, Yue

AU - Huang, Kevin

AU - Magaye, Ruth

AU - Cornell, Jake

AU - Kelly, Darren J.

AU - Reid, Christopher

AU - Liew, Danny

AU - Zhou, Yingchun

AU - Chen, Aihua

AU - Xiao, Wei

AU - Fu, Qiang

AU - Wang, Bing Hui

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Cardiac fibrosis refers to an excessive deposition of extracellular matrix (ECM) in cardiac tissue. Fibrotic tissue is stiffer and less compliant, resulting in subsequent cardiac dysfunction and heart failure. Cardiac fibrosis in the ageing heart may involve activation of fibrogenic signalling and inhibition of anti-fibrotic signalling, leading to an imbalance of ECM turnover. Excessive accumulation of ECM such as collagen in older patients contributes to progressive ventricular dysfunction. Overexpression of collagen is derived from various sources, including higher levels of fibrogenic growth factors, proliferation of fibroblasts and cellular transdifferentiation. These may be triggered by factors, such as oxidative stress, inflammation, hypertension, cellular senescence and cell death, contributing to age-related fibrotic cardiac remodelling. In this review, we will discuss the fibrogenic contributors in age-related cardiac fibrosis, and the potential mechanisms by which fibrogenic processes can be interrupted for therapeutic intent.

AB - Cardiac fibrosis refers to an excessive deposition of extracellular matrix (ECM) in cardiac tissue. Fibrotic tissue is stiffer and less compliant, resulting in subsequent cardiac dysfunction and heart failure. Cardiac fibrosis in the ageing heart may involve activation of fibrogenic signalling and inhibition of anti-fibrotic signalling, leading to an imbalance of ECM turnover. Excessive accumulation of ECM such as collagen in older patients contributes to progressive ventricular dysfunction. Overexpression of collagen is derived from various sources, including higher levels of fibrogenic growth factors, proliferation of fibroblasts and cellular transdifferentiation. These may be triggered by factors, such as oxidative stress, inflammation, hypertension, cellular senescence and cell death, contributing to age-related fibrotic cardiac remodelling. In this review, we will discuss the fibrogenic contributors in age-related cardiac fibrosis, and the potential mechanisms by which fibrogenic processes can be interrupted for therapeutic intent.

KW - ageing

KW - cardiac fibrosis

KW - extracellular matrix turnover

KW - fibrogenic factors

KW - heart failure

UR - http://www.scopus.com/inward/record.url?scp=85030094725&partnerID=8YFLogxK

U2 - 10.1111/1440-1681.12753

DO - 10.1111/1440-1681.12753

M3 - Article

VL - 44

SP - 55

EP - 63

JO - Clinical and Experimental Pharmacology and Physiology

JF - Clinical and Experimental Pharmacology and Physiology

SN - 0305-1870

IS - S1

ER -